Kweldam Charlotte F, van der Kwast Theodorus, van Leenders Geert J
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
Laboratory Medicine Program, University Health Network, Toronto, Canada.
Transl Androl Urol. 2018 Feb;7(1):145-154. doi: 10.21037/tau.2017.12.33.
The management of newly diagnosed prostate cancer is challenging because of its heterogeneity in histology, genetics and clinical outcome. The clinical outcome of patients with Gleason score 7 prostate cancer varies greatly. Improving risk assessment in this group is of particular interest, as Gleason score 7 prostate cancer on biopsy is an important clinical threshold for active treatment. Architecturally, four Gleason grade 4 growth patterns are recognized: ill-formed, fused, glomeruloid and cribriform. The aim of this review is to describe the role of cribriform growth in prostate cancer with respect to diagnosis, prognosis and molecular pathology. Secondly, we will discuss clinical applications for cribriform prostate cancer and give recommendations for future research.
新诊断前列腺癌的管理具有挑战性，因为其在组织学、遗传学和临床结果方面存在异质性。 Gleason评分7分的前列腺癌患者的临床结果差异很大。 由于活检时Gleason评分7分的前列腺癌是积极治疗的重要临床阈值，因此改善该组患者的风险评估尤为重要。 在结构上，公认有四种Gleason 4级生长模式：形态不良、融合、肾小球样和筛状。 本综述的目的是描述筛状生长在前列腺癌的诊断、预后和分子病理学方面的作用。 其次，我们将讨论筛状前列腺癌的临床应用，并为未来研究提出建议。
